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Fas-mediated apoptosis is one of the mechanisms used by tumor cells to escape the cytotoxicity of tumor-
inﬁltrating lymphocytes. It has been suggested that cytokine-induced killer (CIK) cells are resistant to Fas-
mediated apoptosis, thereby rendering them more attractive for use in cellular immunotherapy. Unlike
what was observed by others, here we show that CIK cells are sensitive to Fas-mediated apoptosis. We have
observed an increase in Fas expression in the different CIK cell subpopulations (CD3þCD56, CD3þCD56þ, and
CD3CD56þ) isolated from both cord blood (CB) and peripheral blood (PB). We also show that the bulk, as
well as the CD3þCD56 and CD56þ CB- and PB-CIK cell subpopulations were sensitive to Fas-mediated
apoptosis induced by both CH11 and APO-1 antibodies, albeit with a weaker effect for the CH11 antibody
on CB-CIK cells. In addition, in the presence of the APO-1 and CH11 inducers, Fas engagement inhibited the
cytotoxic activity of CB- and PB-CIK cells. This new contradictory result may help explain the variable efﬁcacy
observed with CIK cells in the clinic.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Technologies, Burlington, ON, Canada) and 10% fetal bovine serum (FBS; Life
The Fas and Fas ligand (FasL) receptor/ligand system is
implicated in lymphocyte homeostasis and peripheral toler-
ance, as well as tumor immunity. Despite other cellular
responses emanating from Fas-FasL interactions, its major
and best-known role is apoptotic cells death [1,2]. Usually, an
effector cell expresses FasL and a target cell expresses Fas, and
this interaction mediates the apoptosis of the target cell. In
contrast, during an immune reaction against tumor cells,
immune effector cells can express both Fas and FasL and
target tumor cells can express FasL, thus leading to the
apoptosis of the effector cell. Cytokine-induced killer (CIK)
cells share similar phenotypic and functional properties as
those of T and natural killer cells. CIK cells can be ampliﬁed
and differentiated from peripheral blood (PB) [3] or cord
blood (CB) [4] by the combined addition of interferon gamma,
interleukin 2, and anti-CD3. Interestingly, it has been shown
that bulk CIK cells were resistant to Fas-mediated apoptosis,
making these cells very attractive potentially for use in
cellular immunotherapy, as they should be able to elude
apoptosis that could be induced by the expression of FasL on
tumor cells [5].
Here, however, in this short report, we show that CIK
cells, isolated from either PB or CB, in our hands are sensitive
to Fas-mediated apoptosis.MATERIAL AND METHODS
Cells
The SU-DHL-4 cell line (DSMZ, Braunschweig, Germany) was main-
tained in RPMI-1640 medium supplemented with 2 mM L-glutamine (Lifedgments on page 1411.
equests: Elie Haddad, Service d’Immu-
iques, CHU Sainte-Justine, 3175 Cote
c H3T 1C5, Canada.
ontreal.ca (E. Haddad).
2013 American Society for Blood and
13.07.007Technologies).
Expansion of CB-CIK and PB-CIK Cells
CB units were obtained from the CHU Sainte-Justine Research CB bank
with approval from the ethics committee. PB samples were collected from
consenting healthy donors. CIK cells from CB mononuclear cells and PB
mononuclear cells were generated as previously described [6].
Extracellular Staining of CB-CIK and PB-CIK Cells
Subpopulations of CB-CIK and PB-CIK cells were stained using anti-
human CD3, antihuman CD56, and antihuman CD95 antibodies (BD Biosci-
ences). Samples were acquired on a FACS Fortessa (BD Biosciences) ﬂow
cytometer and analyzed using FACSDiva (BD Biosciences) or FlowJo software
(Tree Star Inc., Ashland, OR).
51Chromium-release Cytotoxicity Assay
The cytotoxicity assays were conducted as previously described [6]. In
some experiments, before the cytotoxicity assay, antihuman CD95 antibody
(CH11, ﬁnal concentration per well ¼ 1 mg/mL, Beckman Coulter, ON,
Canada) and antihuman APO-1 antibody (APO-1; clone APO-1-3, ﬁnal
concentration per well ¼ 250 ng/mL; Enzo Life Sciences, ON, Canada) were
added with effector cells and incubated for 1 hour. At the end of the 1-hour
incubation with APO-1, an afﬁniPure rabbit antimouse IgG antibody (10 mg/
mL, Jackson ImmunoResearch, PA.) was immediately added. Then, 51Cr
stained-target cells were added in each well. Effector cells with or without
CH11 or APO-1 were added at effector-to-target ratios of 1.25:1, 5:1, 20:1,
and 40:1 and incubated for 4 hours at 37C in a 5% CO2 atmosphere.
Fas-mediated Apoptosis Assays
Cells were plated in RPMI-1640 medium supplemented with 10% FBS
and 2 mM L-glutamine at 2 x 105 cells/well in 96-well ﬂat bottom plates.
Cells were then incubated with antihuman CH11 antibody (1 mg/mL) for
18 hours or with antihuman APO-1 antibody (100 and 250 ng/mL) for 1 hour
at 37C in a 5% CO2 atmosphere. At the end of the 1-hour incubation with
APO-1, the afﬁniPure rabbit antimouse IgG antibody (10 mg/mL) was added
to the cells for an additional 17 hours at 37C in a 5% CO2 atmosphere.
Assessment of Apoptosis
To assess apoptosis, cells were harvested and stained with FITC-labeled
annexin (BD Biosciences) and 7AAD (BD Biosciences) for 15minutes at room
temperature. Then, 300 mL of annexin buffer (1X, BD Biosciences) was added
to cells that were subsequently acquired on a FACS Fortessa ﬂow cytometer
and analyzed using FACSDiva or FlowJo software.
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Figure 1. Expression of Fas on CB- and PB-CIK cells and sensitivity of CB- and PB-CIK cells to Fas-mediated apoptosis. PB mononuclear cells and CB mononuclear cells
were cultured with rhIFNg, rhIL2 and OKT3 over a 28-day period. (A) On days 0, 21, and 28, CB- and PB-CIK cells were stained with anti-CD3, anti-CD56 and anti-CD95
antibodies, and were analyzed by ﬂow cytometry. Mean ﬂuorescence intensity of Fas is shown for each population: CD3þCD56þ, CD3þCD56, and CD3CD56þ CB-
and PB-CIK cells, and activated T cells. T cells from PB mononuclear cells were activated by PHA (3.125 mg/mL) and rhIL2 (40 IU/mL) for 8 days. In the histogram, CB cell
populations are shown as white bars, PB cell populations are shown as black bars and activated T cells are shown as grey bars. Results are represented as the mean
value þ/ SEM. The experiment was repeated 2 to 6 times using independent CB- and PB-CIK cell cultures. *P  .038, **P  .0095, Mann Whitney test (2-tailed). (B) A
representative example of an overlay of Fas expression using ﬂow cytometry for the different subpopulation of CB- and PB-CIK cells on days 0, 21, and 28, and
activated T cells on days 0 and 8. Isotype control is depicted as a grey ﬁlled histogram and day 0, 21, and 28 as thin, bold, and dashed lines, respectively. (C) On day 21,
CD56þ and CD3þCD56 subpopulations were isolated from bulk CB- and PB-CIK cells using CD56 magnetic microbeads. The different fractions (bulk, CD56þ, and
CD3þCD56) were incubated for 18 hours with CH11 (1 mg/mL) or APO-1 (100 ng/mL and 250 ng/mL) antibodies. In the histogram, CB cell populations are shown as
white bars, PB cell populations are shown as black bars, and activated T cells are shown as grey bars. The experiment was repeated 3 times using independent CB- and
PB-CIK cell cultures. *P  .01, **P  .001, Mann Whitney test (2-tailed).
Apoptosis was visualized using annexin and 7AAD. Cells were counted as apoptotic when they were annexinþ/7AAD (early apoptotic), and annexinþ/7AADþ
(late apoptotic). The percent speciﬁc apoptosis was calculated as follows: % speciﬁc apoptosis ¼ ((% of experimental apoptosis) e (% spontaneous apoptosis))/(100 e
spontaneous apoptosis)  100. Results are represented as the mean value þ/ SEM.
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Figure 1. (continued).
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CB-CIK and PB-CIK Cells Are Sensitive to Fas-mediated
Apoptosis
We analyzed the expression of Fas on the 3 subpopula-
tions of CB- and PB-CIK cells on days 0, 21, and 28 of the
culture. As shown in Figure 1A and B, on day 21, Fas was
expressed on CD3þCD56þ, CD3þCD56, and CD3CD56þ CB-
CIK and PB-CIK cell subpopulations, whereas Fas expression
on day 0 was undetectable or very weakly expressed on the
CB-CIK subpopulations and weakly expressed on the PB-CIK
subpopulations. The 3 PB-CIK cell subpopulations expressed
signiﬁcantly stronger Fas than the CB-CIK subpopulations on
day 21 (Figure 1A). The expression of Fas on day 28 was
comparable to day 21 for PB-CIK cells, whereas for CB-CIK
cells, there was a weak not signiﬁcant diminution on day
28. The observed Fas expression was comparable between
PB-CIK cells and T cells activated by PHA and rhIL2 for 8 days,
but not for CB-CIK cells that expressed Fas more weakly.
Given that both CB-CIK and PB-CIK cell subpopulations
expressed Fas, we next wanted to determine if they were
sensitive to Fas-mediated apoptosis. To do this, we used bulk
CB-CIK and PB-CIK cells, as well as CD3þCD56 and CD56þ
(that included CD3þCD56þ and CD3CD56þ cells) puriﬁed
subpopulations. Two known antibody inducers of apoptosis
of Fas-expressing cells, APO-1 and CH11 [5,7], were tested at
the following concentrations: 100 ng/mL and 250 ng/mL forthe APO-1 antibody [8] and 1 mg/mL for the CH11 antibody
[5]. Bulk PB-CIK, CD56þ PB-CIK, and CD3þCD56- PB-CIK cells
were sensitive to Fas-mediated apoptosis when inducedwith
either antibody (Figure 1C), and the percentage of apoptosis
was comparable to that observed with activated T cells. In
addition, bulk, CD56þ, and CD3þCD56 CB-CIK and PB-CIK
cells were signiﬁcantly less sensitive to apoptosis induced
by the CH11 antibody than the APO-1 antibody even when
used at the lower concentration.
Fas Engagement Inhibits CD56þ CIK Cell Antitumor
Cytotoxicity
Finally, we tested if CIK cells, sensitive to Fas, could still
kill tumor cells when they were stimulated to undergo
apoptosis. In this experiment, in which we used a cytotox-
icity assay, the CH11 or the APO-1 antibody, along with an
afﬁniPure rabbit antimouse IgG antibody, were added to
CD56þ CB- and PB-CIK cells (that included CD3þCD56þ and
CD3CD56þ cells). Then, after 1 hour of incubation, SU-DHL-
4 tumor cells were added to effector cells. The cytotoxicity
assay was only done with the CD56þ CIK fraction as we and
others have showed that the CD3þCD56 cells did not
display any cytotoxic activity, and that the main cytotoxic
activity was issued to CD3þCD56þ cells and a few to
CD3-CD56þ cells [6,10]. We chose the SU-DHL-4 cell line as
a target because it was reported to be resistant to Fas-
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Figure 2. Fas engagement inhibits the cytotoxic activity of CD56þ CB- and PB-CIK cells against the SU-DHL-4 cell line. The CD56þ fraction from CB- and PB-CIK cells
were puriﬁed using CD56 magnetic microbeads. The cytotoxic activity of CD56þ CB- and PB-CIK cells was tested against the SU-DHL-4 cell line in the absence (thick
lines) or presence of the CH11 antibody (1 mg/mL; dashed lines) or the APO1 antibody (250 mg/mL; thin lines). Results are represented as the mean value þ/SEM
(n ¼ 2 independent CD56þ CB- and CD56þ PB-CIK cell cultures). The curves with the presence of the CH11 and APO-1 antibodies were compared to the curve without
antibody. *P  .05, **P  .01 and ***P  .001, ANOVA test with a Bonferroni post-test.
L. Durrieu / Biol Blood Marrow Transplant 19 (2013) 1393e14111410mediated apoptosis [9] and because it is the cell line used by
Verneris et al. [5]. As shown in Figure 2, Fas engagement with
CH11 and APO-1 inducers inhibited completely the cytotoxic
activity of CD56þ PB-CIK cells against SU-DHL-4 tumor cells
and only partially but signiﬁcantly of CD56þ CB-CIK cells. We
also conﬁrmed our data when we used exactly the same
protocol that was performed by Verneris et al., ie, by adding
the apoptosis inducers to target cells and effector cells
without preincubation (data not shown).
DISCUSSION
In this short report, we have shown that the different
subpopulations of CB-CIK and PB-CIK cells expressed Fas and
were sensitive to Fas-mediated apoptosis, and that it could
inﬂuence their cytotoxic activity in vitro.
Many research groups have observed in the microenvi-
ronment of several tumors the presence of tumor-inﬁltrating
lymphocytes (TIL) that display cytotoxic activity against
these tumor cells in vitro [11,12]. Tumor cells have developed
several mechanisms to escape the immune system [13]. One
such strategy involves the expression of FasL on tumor cells
that can induce the apoptosis of Fas expressing TILs. FasL has
been detected on cells from various tumor cell lines [14,15].
Also, O’Connell et al. [14] have shown that FasL on colon
cancer cells was functional and could induce the apoptosis of
Jurkat T cells.
Verneris et al. have investigated the sensitivity of PB-CIK
cells to Fas-mediated apoptosis. They have shown that Fas
engagement did not induce apoptosis of PB-CIK cells nor did
it inhibit their antitumor cytotoxicity. In addition, they haveobserved that PB-CIK cells expressed several antiapoptotic
genes such as CFLIP, Bcl-2, Bcl-xL, DAD-1, and survivin. The
expression of these genes could potentially explain why PB-
CIK cells were not sensitive to Fas-mediated apoptosis
because when protein synthesis was inhibited, PB-CIK cells
became sensitive to Fas-mediated apoptosis. They have also
shown that the resistance to apoptosis of PB-CIK cells could
be due to the synthesis of FasL by CIK cells. In the supernatant
of CIK cells, there was, therefore, active soluble FasL that
could act against tumor cells.
Although Verneris et al. showed that bulk PB-CIK, as well
as CD3þCD56 and CD3þCD56þ PB-CIK cell subpopulations,
were resistant to Fas-mediated apoptosis,we found, however,
that bulk PB-CIK and CB-CIK cells, as well as CD3þCD56 and
CD56þ PB- and CB-CIK (that included CD3þCD56þ and
CD3-CD56þ cells) subpopulations, were sensitive to Fas-
mediated apoptosis induced by CH11, also used by Verneris
et al., and APO-1 [8]. In addition, apoptosis of CIK-cells was
signiﬁcantlymore pronouncedwith the APO-1 than the CH11
antibody.
This contradictory result may reﬂect the fact that in our
hands, Fas expression by PB and CB-CIK cells was much
greater than what was observed by Verneris et al., thereby
rendering them sensitive to Fas-mediated apoptosis. Indeed,
we showed that the expression of Fas increased over the
course of the culture period for all 3 subpopulations of PB-
and CB-CIK cells, and by day 21, Fas expression (as measured
by mean ﬂuorescence intensity) was approximately 2 to 4
times greater (between 70 and 120) than that observed by
Verneris et al. (mean ﬂuorescence intensity w 30) at the
L. Durrieu / Biol Blood Marrow Transplant 19 (2013) 1393e1411 1411same time point. This difference of Fas expression is not due
to the antibody because we used the same clone of anti-
human CD95 monoclonal antibody as used by Verneris et al.
We did use a different concentration of OKT3 (50 ng/mL
instead of 25 ng/mL) and a different culture medium (RPMI
instead of X-vivo 15 medium); however, we consider it
unlikely that these modiﬁcations explain the difference in
expression observed. In addition, Verneris et al. did not
always specify if they tested the sensitivity of CIK cells on day
21 or 28. This information is important because they ob-
served a diminution of Fas expression on CIK cells on day 28,
whereas we did observed no or very little diminution on CB-
and PB-CIK cell subpopulations. We also conﬁrmed our data
when we used exactly the same protocol that was used by
Verneris et al., ie, elimination of dead cells and incubation of
cells during 24 hours before the apoptotic assay.
Additionally, we found that the CH11 antibody provoked
signiﬁcantly less apoptosis than the APO-1 antibody. Also,
unlike CH11-induced apoptosis, the APO-1-induced apoptosis
for a given subpopulation (bulk, CD3þCD56, or CD56þ frac-
tions) was similar for CB- and PB-CIK cells. These differences
between APO-1 and CH11may be due to the fact that the CH11
antibody is an IgM,whereas theAPO-1antibody is an IgG.Thus,
the dimeric APO-1 antibody, to provoke an apoptosis signal,
has to be cross-linked by an IgG antimouse antibody, thereby
inducing a more powerful and more consistent apoptosis.
To evaluate if CIK cell sensitivity to Fas-mediated
apoptosis could disrupt the cytotoxic activity of these cells,
we tested the activation of Fas-mediated apoptosis of CD56þ
CB- and PB-CIK cell subpopulations against the SU-DHL-4
cell line. In contrast to those of Verneris et al., in the pres-
ence of CH11 and APO-1 inducers, CD56þ PB-CIK cells were
unable to kill SU-DHL-4 cells, and CD56þ CB-CIK could do
this only partially. The difference between CB- and PB-CIK
cells for both the sensitivity of Fas-induced apoptosis and
their ability to still have a cytotoxic effect on SU-DHL-4 cell
line could be explained by the fact that CB-CIK cell subpop-
ulations displayed a weaker Fas expression than PB-CIK cell
subpopulations. This result is interesting because it suggests
that CD56þ CB-CIK cells could be less sensitive to Fas-
mediated apoptosis than CD56þ PB-CIK cells and may
argue for a better efﬁcacy of CB-CIK cells against tumor cells
that express FasL, although this will have to be conﬁrmed
clinically. Indeed, all our experiments to evaluate the sensi-
bility of CB- and PB-CIK cells to Fas-mediated apoptosis have
been performed in vitro using inducers, and the results may
be different in the clinical situations.
In conclusion, both CB- and PB-CIK cells are sensitive to
Fas-mediated apoptosis but the intensity of the detected
apoptosis depends upon which inducer is used. The sensi-
tivity of CIK cells to Fas-mediated apoptosis could perhaps
explain why the efﬁcacy of CB- and PB-CIK cells was variable
in several patients compared with others. A more detailedunderstanding of the relation between CIK cells and Fas-
mediated apoptosis may help elucidate their shortcomings,
while at the same time suggest ways of enhancing their
clinical antitumor activity.ACKNOWLEDGMENTS
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